NeuraClick Taps Titan Advisors to Revolutionize CNS Drug Discovery

SAN DIEGO, CA – April 15, 2026 – Preclinical biopharmaceutical company NeuraClick, Inc. has signaled a major acceleration in its mission to treat complex brain disorders, announcing the appointment of two world-renowned scientists to its advisory board. The San Diego-based firm has brought on Dr. Gavin S. Dawe, a leading neuropharmacologist, and Dr. Tomi K. Sawyer, a legendary peptide drug hunter, to guide its novel platform toward clinical reality.

The appointments are a significant move for the privately-held company, which is leveraging artificial intelligence and advanced chemistry to engineer a new class of medicines. By recruiting two of the most respected minds in neuropharmacology and peptide therapeutics, NeuraClick is making a bold statement about its ambitions to succeed where many have failed: developing durable, effective treatments for central nervous system (CNS) and neuro-metabolic conditions.

Assembling a Scientific Brain Trust

The addition of Drs. Dawe and Sawyer represents a formidable enhancement of NeuraClick’s intellectual capital. Their combined expertise provides a powerful validation of the company's scientific direction and significantly de-risks its path to the clinic.

Dr. Gavin Dawe joins as Scientific Advisor for Neuropharmacology & Translational Neuroscience. He serves as an Associate Professor and Head of the Department of Pharmacology at the National University of Singapore's Yong Loo Lin School of Medicine. A key opinion leader in neuropeptide neuropharmacology, his research delves into the critical neural systems that regulate stress, arousal, and reward. His work has been recognized with numerous accolades, including the Singapore Neuroscience Association Distinguished Neuroscientist Award and the GSK Academic Centre of Excellence Research Award. With prior industry experience at Eli Lilly and Company and ReNeuron, Dr. Dawe possesses a rare blend of academic rigor and commercial development insight. His role will focus on building the translational bridge from NeuraClick’s lab discoveries to measurable outcomes in patients.

Dr. Tomi K. Sawyer, appointed as Strategic Advisor for Peptide Therapeutics & Partnering Strategy, is a luminary in the field with over four decades of experience. A former President of the American Peptide Society, Dr. Sawyer has an extraordinary track record of translating peptide science into approved medicines. His contributions have led to the marketing of drugs like Scenesse® for a rare skin disorder and Iclusig® for leukemia during his senior leadership tenures at companies including Merck & Co., Aileron Therapeutics, and Ariad Pharmaceuticals. Currently the Founding Chief Drug Hunter at Maestro Therapeutics, he is widely regarded for his ability to shepherd novel drug candidates through the arduous development process. His strategic guidance will be crucial as NeuraClick refines its pipeline and seeks partnerships.

Beyond the Blood-Brain Barrier: The NuClick™ Promise

For decades, the brain has remained one of the most challenging targets for drug developers. Neuropeptides—the body's own signaling molecules for controlling complex brain functions—have long been seen as powerful therapeutic tools, but their therapeutic use has been stymied by two fundamental problems: they are quickly broken down by the body, and they struggle to cross the protective blood-brain barrier.

NeuraClick aims to solve this with its proprietary AI/ML-enabled NuClick™ platform. The technology uses computational design and a chemical process known as macrocyclization, or “stapling,” to re-engineer natural neuropeptides. This process locks the peptides into a more stable, durable structure, designed to resist degradation and improve their ability to reach targets within the brain. The approach is rooted in a prior research collaboration between NeuraClick's founder and CEO, Dr. Subhi Marwari, and Dr. Dawe, which explored the intranasal delivery of stapled peptides for anxiety and depression.

This innovative engineering is at the heart of the company's strategy. “Achieving the right balance of stability, pharmacokinetics, and tissue exposure has long limited the therapeutic potential of peptides,” said Dr. Sawyer in the company's announcement. “NeuraClick’s platform introduces a fundamentally new approach to peptide engineering, grounded in translational design principles, overcoming these constraints and enabling a new generation of durable neuropeptide medicines for CNS disorders.”

Dr. Dawe echoed this sentiment, highlighting the untapped potential of the brain's natural systems. “Neuropeptide systems represent one of the most powerful and underexplored mechanisms for modulating brain circuits underlying complex behaviors,” he stated. “NeuraClick’s strategy to engineer these systems with improved stability and functional control represents an important step toward translating this biology into effective neurotherapeutics.”

Signaling a Strategic Leap Toward Patients

These appointments are more than a scientific coup; they are a clear strategic signal. By bringing in advisors with deep experience in both clinical translation and corporate partnering, NeuraClick is laying the groundwork for its next phase of growth. The company is positioning itself to move its preclinical programs forward and forge the strategic alliances necessary to navigate the costly and complex world of CNS drug development.

The market need is staggering. The global CNS therapeutics market is projected to exceed $220 billion by 2035, driven by the immense burden of conditions like depression, anxiety, and neurodegenerative diseases. According to the World Health Organization, depression is a leading cause of disability worldwide, and existing treatments are often inadequate. By targeting the underlying neurocircuitry with precision-engineered peptides, NeuraClick hopes to offer new hope for millions of patients.

“We are pleased to welcome Gavin and Tomi as we continue building NeuraClick’s scientific and translational foundation,” said Dr. Subhi Marwari, Founder and CEO of NeuraClick. “Their combined expertise strengthens the link between our biological insights and therapeutic development strategy, supporting the advancement of our programs toward clinical translation and strategic partnerships.”

As the biopharmaceutical industry increasingly turns to AI-driven platforms and novel modalities to crack the code of complex diseases, NeuraClick’s approach places it at the intersection of several major trends. With a validated technology platform and now the guidance of two industry titans, the company is poised to become a significant player in the quest for next-generation neurotherapeutics. The journey from the lab to the clinic is long, but with its newly expanded brain trust, NeuraClick has taken a decisive step forward.